1
项与 Anti-CLL1-CD33-NKG2D Bicephali CAR-T(Yake) 相关的临床试验 / Not yet recruiting临床1/2期IIT A Phase I/II Study to Evaluate the Safety and Efficacy of Anti-CLL1-CD33-NKG2D Bicephali CAR-T Cells in Patients With Relapsed/Refractory Acute Myeloid Leukemia
This study is a clinical trial designed to evaluate the safety and efficacy of a new type of CAR-T cell therapy for patients with relapsed/refractory acute myeloid leukemia (AML). The treatment involves modifying the patient's own T cells to target and eliminate leukemia cells more effectively. This is a cutting-edge therapy using anti-CLL1-CD33-NKG2D Bicephali CAR-T cells.
The primary goal of this study is to determine whether this treatment can improve survival and reduce the symptoms of AML in patients whose disease has not responded to standard treatments. Participants will be closely monitored for side effects and the overall effectiveness of the treatment.
Eligibility for this study includes patients who have been diagnosed with relapsed or refractory AML and have not had success with previous therapies. Participation in this study will provide access to an experimental treatment that may offer benefits beyond current treatment options, but also comes with risks.
Patients, their families, and healthcare providers will be provided with full information about the procedure, potential benefits, and risks, and they will have the opportunity to ask questions before deciding whether to participate.
100 项与 Anti-CLL1-CD33-NKG2D Bicephali CAR-T(Yake) 相关的临床结果
100 项与 Anti-CLL1-CD33-NKG2D Bicephali CAR-T(Yake) 相关的转化医学
100 项与 Anti-CLL1-CD33-NKG2D Bicephali CAR-T(Yake) 相关的专利(医药)
100 项与 Anti-CLL1-CD33-NKG2D Bicephali CAR-T(Yake) 相关的药物交易